Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Oct 04, 2022

SELL
$144.95 - $152.29 $42,470 - $44,620
-293 Reduced 6.66%
4,108 $621,000
Q2 2022

Jul 07, 2022

SELL
$83.14 - $145.99 $415 - $729
-5 Reduced 0.11%
4,401 $641,000
Q1 2022

Apr 14, 2022

BUY
$110.08 - $142.92 $7,705 - $10,004
70 Added 1.61%
4,406 $522,000
Q4 2021

Jan 19, 2022

BUY
$99.73 - $148.48 $213,023 - $317,153
2,136 Added 97.09%
4,336 $598,000
Q2 2021

Jul 06, 2021

BUY
$65.78 - $105.02 $144,716 - $231,044
2,200 New
2,200 $214,000
Q4 2020

Feb 04, 2021

SELL
$65.07 - $98.24 $9,760 - $14,736
-150 Closed
0 $0
Q1 2020

May 14, 2020

BUY
$27.51 - $57.29 $4,126 - $8,593
150 New
150 $5,000

Others Institutions Holding BHVN

About Biohaven Pharmaceutical Holding Co Ltd.


  • Ticker BHVN
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,645,000
  • Market Cap $2.8B
  • Description
  • Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...
More about BHVN
Track This Portfolio

Track Advisor Net Financial, Inc Portfolio

Follow Advisor Net Financial, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Net Financial, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Advisor Net Financial, Inc with notifications on news.